Shots:

• The approval is based on P-III DAPA-HF trial involves assessing of Forxiga (10mg- qd) + SOC (ACEi or ARB) vs PBO + SOC in 4-744 patients with HFrEF (LVEF ≤ 40%) with/ out T2D
• The study demonstrated 26% reduction in the risk of the composite of CV death or worsening of HF events- including hHF. The safety profile of Forxiga was consistent with the well-established safety profile of the therapy
• Forxiga is the first SGL2 inhibitor- currently being tested for HFpEF in the DELIVER P-III trial with its anticipated data in the H1’21

 ­ Ref: AstraZeneca | Image: The Scientist Magazine